We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pharma Pushes FDA to Speed Up Five-Year Exclusivity for Combo Drugs
Pharma Pushes FDA to Speed Up Five-Year Exclusivity for Combo Drugs
Drugmakers are enthusiastic supporters of the FDA’s plans to offer five years of market exclusivity for more fixed-dose combination products — but they want the agency to broaden its new policy so it will cover products already under review.